NEW YORK (GenomeWeb News) – Dako today announced that the US Food and Drug Administration has approved its HER2 IQFISH pharmDx assay for marketing in the US.

HER2 IQFISH pharmDx is a fluorescence in situ hybridization assay based on Dako's "instant quality in situ hybridization" buffer chemistry, and according to the firm, the assay will reduce the cancer diagnosis turnaround time to three-and-a-half hours from the current two days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.